Alteration of the fibrinogen molecule and its phosphorylation state in myocardial infarction patients undergoing thrombolytic treatment

Thrombosis Research

Volumn 98, Issue 2, 2000, Pages 147-156

  Haglund, Åsa C ^a   Ronquist, Gunnar ^b   Frithz, Göran ^c   Ek, Pia ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Central Hospital   (Sweden)

Author keywords

AMI; Fibrinogen; Phosphorylation

Indexed keywords

AGAROSE; ALTEPLASE; FIBRINOGEN; FIBRINOLYTIC AGENT; PHOSPHATE; PROTAMINE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CASE REPORT; CHROMATOGRAPHY; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MYOCARDIAL INFARCTION; PHOSPHORYLATION; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034655290     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00225-X     Document Type: Article

References (39)

1. Brennan S.O. Electrospray ionisation analysis of human fibrinogen. Thromb Haemost. 78:1997;1055-1058.
2. Handley D.A., Hughes T.E. Pharmacological approaches and strategies for therapeutic modulation of fibrinogen. Thromb Res. 87:1997;1-36.
3. Holm B., Nilsen D.W.T., Kierulf P., Godal H.C. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res. 37:1985;165-176.
4. Finlayson J., Mosesson M. Heterogeneity of human fibrinogen. Biochemistry. 2:1963;42-46.
5. Holm B., Godal H.C. Quantitation of three normally occurring plasma fibrinogens in health and during so-called "acute-phase" by SDS electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res. 35:1984;279-290.
6. Reganon E., Vila V., Aznar J., Laiz B. Human fibrinogen heterogeneity. A study of limited fibrinogen degradation. Clin Chim Acta. 184:1989;7-17.
7. Nakashima A., Sasaki S., Miyazaki K., Miyata T., Iwanaga S. Human fibrinogen heterogeneity. The COOH-terminal residues of defective A alpha chains of fibrinogen II Blood Coagul Fibrinolysis. 3:1992;361-370.
8. Watt K., Cottrell B., Strong D., Doolittle R. Amino acid sequence studies of the alpha chain of human fibrinogen. Overlapping sequences providing the complete sequence. Biochemistry. 18:1979;5410-5416.
9. Blombäck B., Blombäck M., Edman P., Hessel B. Amino-acid sequence and the occurrence of phosphorous in human fibrinopeptides. Nature. 193:1962;883-884.
10. Seydewitz H.H., Kaiser C., Rothweiler H., Witt I. The location of a second in vivo phosphorylation site in the Aα-chain of human fibrinogen. Thromb Res. 33:1984;487-498.
11. Blombäck B., Blombäck M., Searle J. On the occurrence of phosphorus in fibrinogen. Biochim Biophys Acta. 74:1963;148-151.
12. Ekman P., Jäger O. Quantification of subnanomolar amounts of phosphate bound to seryl and threonyl residues in phosphoproteins using alkaline hydrolysis and malachite green. Anal Chem. 214:1993;138-141.
13. Hanna L., Scheraga H., Francis C., Marder V. Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides. Biochemistry. 23:1984;4681-4687.
14. Seydewitz H.H., Matthias F.R., Schöndorf T.H., Witt I. Increase in the degree of phosphorylation of circulating fibrinogen under thrombolytic therapy with urokinase. Thromb Res. 46:1987;437-445.
15. Seydewitz H.H., Witt I. Increased phosphorylation of human fibrinopeptide A under acute phase conditions. Thromb Res. 40:1985;29-39.
16. Reganon E., Vila V., Aznar J., Lacueva V., Martinez V., Ruano M. Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increase in the rate of fibrinopeptide release. Thromb Haemost. 70:1993;978-983.
17. Reganon E., Vila V., Laiz B., Gilabert J., Aznar J. Decreased high-molecular weight fibrinogen and impaired alpha-chain polymerization in full-term newborns. Haemostasis. 23:1993;149-158.
18. Martin S.C., Ekman P., Forsberg P.-O., Ersmark H. Increased phosphate content of fibrinogen in vivo correlates with alteration in fibrinogen behaviour. Thromb Res. 68:1992;467-473.
19. Suk K., Lee J.-Y., Kim S.-H. Synergistic stimulation of fibrinogen gelation by casein kinase II and polycationic compounds. Biochem Mol Biol Int. 42:1997;487-495.
20. Martin S.C., Forsberg P.-O., Eriksson S.D. The effects of in vitro phosphorylation and dephosphorylation on the thrombin-induced gelation and plasmin degradation of fibrinogen. Thromb Res. 61:1991;243-252.
21. Arntz H.-R., Perchalla G., Roll D., Heitz J., Schäfer J.-H., Schröder R. Blood rheology in acute myocardial infarction. Effects of high-dose i.v. streptokinase compared to placebo Eur Heart J. 13:1992;275-280.
22. Osterman H., Schmitz-Huebner U., Windeler J., Bär F., Meyer J., van den Loo J. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction - Results from the PRIMI trial. Eur Heart J. 13:1992;1225-1232.
23. Rao A., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T., Bell W., Knatterud G., Robertson T., Terrin M. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol. 11:1988;1-11.
24. Samama M., Nguyen G., Desnoyers P., Lourenco D., Fretault J., Horellou M., Conard J., Szwarcer E., Verdy E., Vahaanian A. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro. Fundam Clin Pharmacol. 2:1988;509-523.
25. Vila V., Regañon E., Aznar J., Lacueva V., Ruano M., Laiz B. Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase. Thromb Res. 57:1990;783-794.
26. Dempfle C.E., Heene D.L. Purification of human plasma fibrinogen by chromatography on protamine-agarose. Thromb Res. 46:1987;19-27.
27. Dempfle C.E., Heene D.L. Isolation and purification of fibrinogen/fibrin degradation products by chromatography on protamine-agarose. Thromb Res. 48:1987;223-232.
28. O'Farrell P. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 250:1975;4007-4021.
29. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
30. Okada M., Blombäck B., Chang M.-D., Horowitz B. Fibronectin and fibrin gel structure. J Biol Chem. 260:1985;1811-1820.
31. Dempfle C.-E., Pfitzner S.A., Schott D., Niessen K.-H. Fibrinogen heterogeneity in homozygous plasminogen deficiency type I. Further evidence that plasmin is not involved in formation of LMW- and LMW′-fibrinogen Thromb Haemost. 77:1997;879-883.
32. Tanswell P., Seifried E., Su P., Feuerer W., Rijken D. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther. 46:1989;155-162.
33. Jan K., Powers E., Reinhart W., Berke A., Nichols A., Watson R., Reison D., Schwartz A., Chien S. Altered rheological properties of blood following administration of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction. Adv Exp Med Biol. 281:1990;409-417.
34. Stangl K., Laule M., Tenckhoff B., Stangl V., Gleich V., Dubel P., Grohmann A., Melzer C., Langel J., Wernecke K., Baumann G., Ziemer S. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction. Am J Cardiol. 81:1998;841-847.
35. Seifried E., Oethinger M., Tanswell P., Hoe gee-de Nobel E, Nieuwenhuizen W Influence on acute myocardial infarction and rt-PA therapy on circulating fibrinogen. Thromb Haemost. 69:1993;321-327.
36. Stump D., Califf R., Topol E., Sigmon K., Thornton D., Masek R., Anderson L., Collen D. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. Circulation. 80:1989;1222-1230.
37. Blombäck B., Blombäck M., Edman P., Hessel B. Human fibrinopeptides. Isolation, characterization and structure. Biochim Biophys Acta. 115:1966;371-396.
38. Cooper J. Estimation of phosphorylation stoichiometry by separation of phosphorylated isoforms. Methods Enzymol. 201:1991;251-261.
39. src at a novel site. Cell. 42:1985;849-857.